UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Inovio Pharma (INO)

Inovio Pharma (INO)
1.5200 x 10 1.5700 x 50
Post-market by (Cboe BZX)
1.5600 -0.0300 (-1.89%) 04/04/25 [NASDAQ]
1.5200 x 10 1.5700 x 50
Post-market 1.5700 +0.0100 (+0.64%) 19:57 ET
Profile for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.

Company Info

Inovio Pharma 660 W. GERMANTOWN PIKE SUITE 110 PLYMOUTH MEETING PA 19462 USA

www.inovio.com Employees: 134 P: 267-440-4200

Sector:

Medical

Description:

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

Key Statistics

Overview:

Market Capitalization, $K 57,201
Enterprise Value, $K -8,609
Shares Outstanding, K 36,667
Annual Sales, $ 220 K
Annual Net Income, $ -107,250 K
Last Quarter Sales, $ 120 K
Last Quarter Net Income, $ -19,380 K
EBIT, $ -112,400 K
EBITDA, $ -109,270 K
60-Month Beta 1.84
% of Insider Shareholders 2.50%
% of Institutional Shareholders 26.79%
Float, K 35,750
% Float 97.50%
Short Volume Ratio 0.49

Growth:

1-Year Return -86.95%
3-Year Return -96.02%
5-Year Return -98.40%
5-Year Revenue Growth -94.65%
5-Year Earnings Growth 70.93%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.69 on 03/18/25
Next Earnings Date 05/12/25
Earnings Per Share ttm -4.08
EPS Growth vs. Prev Qtr 22.47%
EPS Growth vs. Prev Year -34.48%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 01/25/24

INO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -132.12%
Return-on-Assets % -91.12%
Profit Margin % -48,750.00%
Debt/Equity 0.00
Price/Sales 267.43
Price/Cash Flow N/A
Price/Book 0.84
Book Value/Share 1.90
Interest Coverage -594.83
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades